Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma

BACKGROUND: Gemcitabine (GEM) plus nab‐paclitaxel (NabP) (GEM 1000 mg/m(2) IV over 30 minutes + NabP 125 mg/m(2) IV given days 1, 8, and 15 every 28 days) is one of the two standard of care combination therapies for metastatic pancreatic ductal adenocarcinoma (PDAC). Our cancer center has utilized G...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Med
Auteurs principaux: Rogers, Jane E., Mizrahi, Jonathan D., Xiao, Lianchun, Mohindroo, Chirayu, Shroff, Rachna T., Wolff, Robert, Varadhachary, Gauri R., Javle, Milind M., Overman, Michael, Fogelman, David R., Raghav, Kanwal P. S., Pant, Shubham, McAllister, Florencia
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2020
Sujets:
Clinical Cancer Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7402810/
https://ncbi.nlm.nih.gov/pubmed/32519420
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3229
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires